Table 2. Comparisons different PD-1/PD-L1 clinical trials results between Asiatic and Caucasian population.
| Trial results | Squamous NSCLC | Non-squamous NSCLC | |||||
|---|---|---|---|---|---|---|---|
| Checkmate017 | Japic CTI-132072 | Checkmate078 | Checkmate057 | Japic CTI-132072 | Checkmate078 | ||
| N | 135 | 35 | 133 | 292 | 76 | 205 | |
| ORR, % | 20.0 | 25.7 | 16.6 | 19.0 | 22.4 | 16.6 | |
| Median PFS (months) | 3.5 | 4.2 | 2.8 | 2.3 | 2.8 | 2.8 | |
| OS (months) | 9.2 | 16.3 | 12.3 | 12.2 | 17.1 | 11.9 | |
| 3–4 grade Tr-AEs (%) | 7.0 | 5.7 | 10.4 | 10.0 | 6.5 | 10.4 | |
| All grades Tr-AEs (%) | 58.0 | 68.6 | 64.1 | 69.0 | 84.2 | 64.1 | |
| Hepato-toxicity | Unknown | 5.7 | 18.0 | Unknown | 6.6 | 18.0 | |
| Pulmonary toxicity | 5.0 | 5.7 | 7.0 | 3.0 | 7.9 | 7.0 | |
NSCLC, non-small cell lung cancer; PFS, progression-free survival; OS, overall survival; Tr-AEs, treatment-related adverse events; ORR, objective response rate.